I've told the story several times. But at the risk of being repetitive, I'll tell it again...

Back in the 1999 to 2000, I was listening to an investor conference call in which Merck's (NYSE:MRK) chief executive, Raymond Gilmartin was speaking.

After running through a litany of reasons why he thought that Merck was well-positioned to grow in the future, an analyst asked whether the company was planning to merge, combine or otherwise acquire another large drug maker.

The question was particularly relevant as a number of high-profile pharmaceutical firms had recently combined forces or were planning large-scale combinations.

Gilmartin nixed the idea right off the bat, essentially saying (and this is my interpretation of his response) that Merck didn't need to combine forces because the company was No. 1.

Perhaps not surprisingly, Gilmartin ended up eating a big slice of humble pie as Merck's drug pipeline languished, and its earnings paled in comparison to those at some of the other big pharmas.

What i found really disturbing about the whole event was that by so readily dismissing the idea of combining forces with another big player, Gilmartin essentially took a potential stock-driving (or supporting) catalyst right off the table. Soon after those comments were made Merck's stock was relegated to the doghouse - between 2001 and 2005 the company saw its stock price almost cut in half.

Merck Hasn't Learned
Earlier this week, I was perusing the news and I came across an article in which Merck's president for Europe, the Middle East, Africa and Canada, Stefan Oschmann, said that he thought that the U.S. drug maker might be interested in bulking up its pipeline by purchasing biotech firms - particularly those with late-stage drugs in the hopper. This seemed good.

However, in conjunction with these comments he also indicated that a large-scale mega merger probably wasn't in the cards. Specifically Oschmann said, "Mega mergers have in most cases not delivered what they had promised ... We don't necessarily think that a mega merger is the right thing."

I just don't get it. The company has the obligation to tell the truth, particularly to its shareholders. However, to taking that potential catalyst off the table again is just a questionable move.

Merck's stock has made a nice comeback over the last year, and is now pretty valuable currency. Plus Merck's reputation seems to be on the mend. You'd think that it would want to keep the momentum going by aggressively scooping up smaller companies or keeping its options open and at least kicking the tires of possible pharma targets?

The Bottom Line
As I mentioned in my last piece on MRK, I think the shares are a 'buy', and I still stick by that. (To read the entire article, see Two Big Names With Big Upside (PG, MRK) .)

However, I am really put off by Oschmann's comments. Going forward, I hope that management learns to keep its options open, and to remember that a few simple words can have a big impact on the share price.

Looking to cook up a market-stomping stock portfolio? Check out our FREE report "7 Ingredients to Market Beating Stocks" and get started right now!

Related Articles
  1. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  2. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  3. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  4. Retirement

    Roth IRAs Tutorial

    This comprehensive guide goes through what a Roth IRA is and how to set one up, contribute to it and withdraw from it.
  5. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  6. Options & Futures

    What Does Quadruple Witching Mean?

    In a financial context, quadruple witching refers to the day on which contracts for stock index futures, index options, and single stock futures expire.
  7. Options & Futures

    4 Equity Derivatives And How They Work

    Equity derivatives offer retail investors opportunities to benefit from an underlying security without owning the security itself.
  8. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  9. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  10. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
RELATED FAQS
  1. What is a derivative?

    A derivative is a contract between two or more parties whose value is based on an agreed-upon underlying financial asset, ... Read Full Answer >>
  2. What is after-hours trading? Am I able to trade at this time?

    After-hours trading (AHT) refers to the buying and selling of securities on major exchanges outside of specified regular ... Read Full Answer >>
  3. How do hedge funds use equity options?

    With the growth in the size and number of hedge funds over the past decade, the interest in how these funds go about generating ... Read Full Answer >>
  4. Can mutual funds invest in options and futures? (RYMBX, GATEX)

    Mutual funds invest in not only stocks and fixed-income securities but also options and futures. There exists a separate ... Read Full Answer >>
  5. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  6. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center